GleamWall
中文EN

OTLC Oncotelic Therapeutics, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 908259 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY14,923.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE181.6%
ROA117.3%
ROIC (approx.)-3.2%
Asset turnover—

Leverage & solvency

Liabilities / assets33.4%
Debt / equity0.00x
Current ratio0.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.01x
Accruals ratio118.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$250,000——————
R&D expense$1,622$345$795$3,337$426$297$297—
SG&A expense$231,053$1.09M$1.85M$2.53M$490,547$65,672$100,803$32,666
Operating income-$232,675-$843,565-$1.85M-$2.53M-$490,973-$65,969-$101,100-$31,454
Interest expense$286,727$318,292——$231,338$207,780——
Net income-$1.11M$388,147-$2.19M$250.35M-$1.05M$277,856-$298,716-$600,934
EPS (basic)0.000.000.00—0.000.000.00—
EPS (diluted)0.000.000.00—0.000.000.00—
Weighted avg. shares (diluted)457.22M467.91M443.80M—426.44M452.81M407.42M—
Balance sheet
Cash & equivalents$63,798$186,014$63,614$88,857$409,000$88,022$79,173$86,128
Receivables$2,057$2,058$2,058$51,324$3,976$18,976$18,976$18,976
Current assets$1.27M$1.46M$2.07M$1.20M$1.61M$137,592$124,993$134,211
Goodwill$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M
Total assets$393.81M$394.75M$393.96M$393.09M$28.16M$26.68M$26.67M$26.68M
Current liabilities$18.04M$17.91M$18.40M$18.14M$20.08M$19.29M$19.48M$19.20M
Short-term debt—————$2.72M$2.58M$2.42M
Total liabilities$131.52M$131.31M$131.74M$131.36M$20.08M$19.29M$19.48M$19.20M
Shareholders' equity$263.47M$264.56M$263.29M$262.76M$9.05M$8.30M$8.02M$8.25M
Shares outstanding457.51M457.01M444.20M442.60M439.45M408.29M408.29M407.29M
Cash flow statement
Operating cash flow-$342,216-$92,197-$342,243-$783,017-$307,022-$126,151-$166,955-$103,880
Financing cash flow$220,000$214,597$317,000$462,874$628,000$135,000$160,000$41,000
Stock-based compensation$63,389$730,410$1.64M$2.20M$183,742$0$0$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.